Company intelligence / Profile preview

Cells4Life

Burgess Hill, West Sussex, United Kingdomcells4life.com ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Over its history, Cells4Life has released at least 17 samples for therapy as of end of 2022. It was the first UK private bank to provide both cord tissue and placenta banking services. The company’s technologies aim to maximize viable stem cell yield for future treatments. Clinical results are based on sample releases rather than direct interventional trials.

Therapeutic areas: Neurology
Modalities: Stem cells (umbilical cord blood stem cells, cord tissue stem cells, placental stem cells including amniotic membrane and chorionic villi)
Industry: Non-Drug Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly listed.

Beyond the preview

Go deeper on Cells4Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cells4Life.

Explore the full profile